Teva Leapfrogs Mylan And Sandoz On Linaclotide
Settlement Permits Generic Linzess Launch In 2029
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
You may also be interested in...
Teva will pay out more than $1m as part of a settlement deal over Intuniv (guanfacine) involving indirect purchasers, newly-filed court documents reveal. Meanwhile, the firm has also just gained a 2029 entry date for a 72mcg strength of its linaclotide rival to Linzess through a separate settlement.
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.